ArticleCell death discovery2023
Correction: In vitro CRISPR screening uncovers CRTC3 as a regulator of IFN-γ-induced ferroptosis of hepatocellular carcinoma.
Li Li, Tao Xing, Yiran Chen, Weiran Xu, Bo Fan, Gaoda Ju, Jing Zhao, Li Lin, Cihui Yan, Jun Liang and 1 more
Open access · goldAbstract readPublished Erratum
In one paragraphArticle in Cell death discovery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 56% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
11 authors at 6 institutions in 2 countries.
Li Li *Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Tao Xing *Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
Yiran Chen *Department of Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China.
Weiran Xu *Department of Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Bo FanBeijing Chao-Yang Hospital, Beijing, China.
Gaoda JuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
Jing ZhaoDepartment of Pathology and Neuropathology, University Hospital Tübingen, Tübingen, Germany.
Li LinDepartment of Oncology, Peking University International Hospital, Beijing, China.
Cihui YanDepartment of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China. cihuiyan@tmu.edu.cn.ORCID http://orcid.org/0000-0002-9391-0403 Xiubao RenDepartment of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China. renxiubao@tjmuch.com.ORCID http://orcid.org/0000-0003-4137-2049 Peking University · CNTianjin Medical University Cancer Institute and Hospital · CNBeijing Chao-Yang Hospital, Capital Medical University · CNCapital Medical University · CNFujian Medical University · CNUniversity Children's Hospital Tübingen · DE
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Identifiers
PMID38110330
PMCPMC10728203
OpenAlexW4389891840
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390